Wall Street analysts expect LivaNova PLC (NASDAQ:LIVN) to report $0.72 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for LivaNova’s earnings. The highest EPS estimate is $0.75 and the lowest is $0.70. LivaNova posted earnings per share of $0.78 in the same quarter last year, which indicates a negative year-over-year growth rate of 7.7%. The business is expected to report its next quarterly earnings report on Wednesday, October 30th.
On average, analysts expect that LivaNova will report full year earnings of $3.03 per share for the current financial year, with EPS estimates ranging from $3.00 to $3.05. For the next financial year, analysts forecast that the business will report earnings of $3.40 per share, with EPS estimates ranging from $3.25 to $3.56. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover LivaNova.
LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, July 31st. The company reported $0.56 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.59 by ($0.03). LivaNova had a positive return on equity of 8.56% and a negative net margin of 23.86%. The firm had revenue of $277.20 million during the quarter, compared to the consensus estimate of $275.14 million. During the same quarter in the previous year, the firm earned $0.96 EPS. The business’s quarterly revenue was down 3.6% compared to the same quarter last year.
Several research firms have commented on LIVN. Piper Jaffray Companies set a $90.00 price objective on shares of LivaNova and gave the company a “buy” rating in a report on Friday, September 6th. BTIG Research reissued a “hold” rating on shares of LivaNova in a research report on Wednesday, July 31st. Zacks Investment Research raised shares of LivaNova from a “hold” rating to a “strong-buy” rating and set a $89.00 target price for the company in a research report on Wednesday, August 7th. Berenberg Bank reissued a “buy” rating and issued a $114.00 target price on shares of LivaNova in a research report on Monday. Finally, ValuEngine raised shares of LivaNova from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $105.57.
In related news, CFO Thad Allen Huston sold 2,000 shares of the stock in a transaction on Monday, August 12th. The stock was sold at an average price of $81.49, for a total value of $162,980.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Damien Mcdonald sold 1,000 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $72.60, for a total value of $72,600.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 14,500 shares of company stock worth $1,140,485. 0.41% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of LIVN. US Bancorp DE increased its holdings in LivaNova by 11.5% in the 2nd quarter. US Bancorp DE now owns 1,452 shares of the company’s stock worth $104,000 after acquiring an additional 150 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in LivaNova by 8.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,900 shares of the company’s stock worth $137,000 after purchasing an additional 155 shares during the period. Rockefeller Capital Management L.P. boosted its stake in LivaNova by 9.6% in the 1st quarter. Rockefeller Capital Management L.P. now owns 1,981 shares of the company’s stock worth $193,000 after purchasing an additional 174 shares during the period. Oregon Public Employees Retirement Fund boosted its stake in LivaNova by 1.2% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 19,448 shares of the company’s stock worth $1,891,000 after purchasing an additional 232 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in LivaNova by 3.9% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,994 shares of the company’s stock worth $575,000 after purchasing an additional 300 shares during the period. Institutional investors own 90.87% of the company’s stock.
Shares of NASDAQ:LIVN traded down $0.99 on Monday, hitting $85.36. The company had a trading volume of 11,269 shares, compared to its average volume of 512,214. LivaNova has a 1-year low of $64.80 and a 1-year high of $131.54. The stock has a market cap of $3.89 billion, a price-to-earnings ratio of 27.01, a P/E/G ratio of 3.15 and a beta of 0.58. The stock has a 50 day moving average price of $78.22 and a 200 day moving average price of $78.24. The company has a current ratio of 0.95, a quick ratio of 0.67 and a debt-to-equity ratio of 0.15.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV?) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
See Also: What is channel trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.